As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Welcome to the Wall Street Week newsletter, bringing you stories of capitalism about things you need to know, but even more ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

We ranked the 10 best commercials from the 2025 Super Bowl and found them online so you can judge them for yourself.

The UK Chancellor’s messaging at Davos recalled former Taoiseach Enda Kenny’s efforts to extol the recovery of the Irish ...

Pfizer’s CEO Ian Read is to step down after eight years and will be replaced on 1st January by chief operating officer Albert Bourla. In contrast to Merck & Co. which has rescinded a company ...

Elon Musk’s Department of Government Efficiency is here, and defense contractors can’t wait for the “revolution” to reach the ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while reiterating a Buy rating on the stock. Currently trading at $25.72, near its 52-week ...

The Genesis Prize Foundation’s Stan Polovets highlights the impact of Thessaloniki's Holocaust Museum and global efforts ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...